The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 24660890 |
12 |
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. |
Merck |
| 22850208 |
60 |
Dipeptidyl peptidase-4 inhibitor withß-amino amide scaffold: synthesis, SAR and biological evaluation. |
Dong-A Pharm. |
| 19217790 |
68 |
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. |
Matrix Laboratories |
| 18201067 |
276 |
Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines. |
Merck Research Laboratories |
| 19539471 |
130 |
Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. |
Merck |
| 17433672 |
16 |
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. |
Merck Research Laboratories |
| 31747282 |
10 |
Discovery of Highly Polar ?-Homophenylalanine Derivatives as Nonsystemic Intestine-Targeted Dipeptidyl Peptidase IV Inhibitors. |
University of Chinese Academy of Sciences |
| 28442252 |
62 |
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome. |
Ranbaxy Laboratories |
Search and Browse
